Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

AEON Biopharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- MEETING DATE ALIGNS WITH PRIOR GUIDANCE - - FDA TO REVIEW AEON'S ANALYTICAL DEVELOPMENT PLAN AND INITIAL DATA - IRVINE, CALIF., OCT. 01, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A BIOPHARMACEUTICAL COMPANY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS SCHEDULED A BIOSIMILAR BIOLOGICAL PRODUCT DEVELOPMENT (BPD) TYPE 2A MEETING FOR ABP-450 ON NOVEMBER 19, 2025, IN LINE WITH PRIOR GUIDANCE.

AEON BIOPHARMA ANNOUNCES FDA BPD TYPE 2A MEETING FOR ABP-450 ON NOVEMBER 19

 MULTIPLE NEAR-TERM POTENTIAL MILESTONES, INCLUDING ANTICIPATED COMPLETION OF PRIMARY STRUCTURE ANALYSIS AND SELECT FUNCTIONAL ANALYSES IN 3Q'25   TYPE 2A MEETING WITH THE FDA ANTICIPATED IN 4Q'25  CASH RUNWAY EXPECTED TO SUPPORT OPERATIONS THROUGH FDA MEETING AND REGULATORY FEEDBACK  IRVINE, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A BIOPHARMACEUTICAL COMPANY SEEKING AN ACCELERATED AND FULL-LABEL U.S. MARKET ENTRY BY DEVELOPING ABP-450 (PRABOTULINUMTOXINA) AS A BOTOX (ONABOTULINUMTOXINA) BIOSIMILAR, ANNOUNCED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A BUSINESS UPDATE.

AEON BIOPHARMA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

HEXAGON LEVERAGES INDUSTRY-LEADING EXPERTISE IN MEASUREMENT TECHNOLOGIES, AI AND AUTONOMOUS SYSTEMS TO INTRODUCE AN ADVANCED HUMANOID ROBOT TO ACCELERATE NEXT-GENERATION AUTONOMY AEON COMBINES BEST-IN-CLASS LOCOMOTION, SENSOR FUSION, AND AI-BASED SPATIAL INTELLIGENCE TO ADDRESS LABOUR SHORTAGES AND TACKLE INDUSTRIAL USE CASES SCHAEFFLER AND PILATUS WILL PILOT THE HUMANOID ACROSS A VARIETY OF USE CASES AND ENVIRONMENTS STOCKHOLM , JUNE 17, 2025 /PRNEWSWIRE/ --HEXAGON, THE GLOBAL LEADER IN MEASUREMENT TECHNOLOGY, LAUNCHES A HUMANOID ROBOT, AEON, AT ITS FLAGSHIP HEXAGON LIVE GLOBAL EVENT. AEON, LAUNCHED BY HEXAGON'S PREVIOUSLY ANNOUNCED ROBOTICS DIVISION, HAS BEEN SPECIFICALLY DESIGNED TO MEET REAL-WORLD CUSTOMER NEEDS AND ADDRESS LABOUR SHORTAGES.

HEXAGON LAUNCHES AEON, A HUMANOID BUILT FOR INDUSTRY

IRVINE, CALIF., MAY 23, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, TODAY REPORTED THE GRANT IN MAY OF 102,880 RESTRICTED STOCK UNITS (RSUS) OF THE COMPANY'S COMMON STOCK TO NEWLY HIRED NON-EXECUTIVE EMPLOYEES OF THE COMPANY. THE AWARDS WERE APPROVED BY THE COMPANY'S BOARD OF DIRECTORS UNDER THE AEON 2025 INDUCEMENT INCENTIVE PLAN, WHICH A GRANT DATE AND VESTING COMMENCEMENT DATE OF MAY 21, 2025.

AEON BIOPHARMA REPORTS INDUCEMENT GRANTS UNDER NYSE AMERICAN LLC COMPANY GUIDE SECTION 711

IRVINE, CALIF., MAY 19, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, TODAY ANNOUNCED THAT ROB BANCROFT, AEON'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT A CORPORATE OVERVIEW AT THE AEGIS CAPITAL CORP. 2025 VIRTUAL CONFERENCE ON WEDNESDAY, MAY 21ST AT 7:00 A.M. PT / 10:00 AM ET.

AEON BIOPHARMA TO PRESENT AT THE AEGIS CAPITAL CORP. VIRTUAL CONFERENCE 2025

 CONTINUE TO CONDUCT ANALYTICAL STUDIES TO PREPARE FOR A POTENTIAL BIOSIMILAR BIOLOGICAL PRODUCT DEVELOPMENT (BPD) TYPE 2A MEETING WITH THE FDA IN THE SECOND HALF OF 2025 

AEON BIOPHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

IRVINE, CALIF., APRIL 25, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, ANNOUNCED TODAY IT HAS RECEIVED NOTIFICATION (THE ACCEPTANCE LETTER) FROM THE NYSE AMERICAN LLC (NYSE AMERICAN) THAT NYSE AMERICAN HAS ACCEPTED THE COMPANY'S PREVIOUSLY SUBMITTED PLAN (THE PLAN) TO REGAIN COMPLIANCE WITH NYSE AMERICAN'S CONTINUED LISTING STANDARDS SET FORTH IN SECTIONS 1003(A)(I), (II) AND (III) OF THE NYSE AMERICAN COMPANY GUIDE (THE COMPANY GUIDE) RELATING TO MINIMUM MARKET CAPITALIZATION AND STOCKHOLDERS' EQUITY.

AEON BIOPHARMA ANNOUNCES NYSE AMERICAN ACCEPTANCE OF PLAN TO REGAIN LISTING COMPLIANCE

IRVINE, CALIF., APRIL 21, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, TODAY ANNOUNCED THAT, IN CONNECTION WITH THE APPOINTMENT OF ROB BANCROFT AS PRESIDENT AND CHIEF EXECUTIVE OFFICER, THE COMPANY'S COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS HAS APPROVED THE GRANT OF INDUCEMENT AWARDS.

 FORMER CEO, MARC FORTH, TO REMAIN AS A MEMBER OF THE COMPANY'S BOARD OF DIRECTORS   FORMER CEO, MARC FORTH, TO REMAIN AS A MEMBER OF THE COMPANY'S BOARD OF DIRECTORS 

AEON BIOPHARMA APPOINTS INDUSTRY VETERAN ROB BANCROFT AS CHIEF EXECUTIVE OFFICER

 MARC FORTH STEPS DOWN AS PRESIDENT AND CEO TO PURSUE ANOTHER OPPORTUNITY; WILL REMAIN ON THE BOARD OF DIRECTORS   JOST FISCHER, CHAIRMAN OF AEON, WILL ASSUME THE ROLE OF INTERIM CEO  IRVINE, CALIF., MARCH 27, 2025 (GLOBE NEWSWIRE) -- AEON BIOPHARMA, INC. (AEON OR THE COMPANY) (NYSE: AEON), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING A BOTULINUM TOXIN COMPLEX FOR THE TREATMENT OF MULTIPLE THERAPEUTIC INDICATIONS, ANNOUNCED TODAY A LEADERSHIP TRANSITION UNDER WHICH MARC FORTH IS STEPPING DOWN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF THE COMPANY TO PURSUE ANOTHER OPPORTUNITY, EFFECTIVE APRIL 4, 2025.

AEON Biopharma, Inc.

AEON

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AEON Biopharma, Inc.

AEON.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AEON